The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 30.1
Myelodysplastic Syndromes, Chronic Myeloproliferative Disorders, and Chronic Myelomonocytic Leukemia
Counts, Percents and Age-Adjusted Incidence Ratesa by Subtype
21 SEER Geographic Areas 2012-2016
All Myelodysplastic syndromes (MDS),
Chronic myeloproliferative disorders (CMD),
Chronic myelomonocytic leukemia (CMML)
| Site | Both Sexes | Males | Females | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Count | Percent | Rate | Count | Percent | Rate | Count | Percent | Rate | |
| Total | 51,194 | 100.0% | 8.1 | 27,832 | 100.0% | 10.2 | 23,362 | 100.0% | 6.6 |
Myelodysplastic Syndromes (MDS)
| Site | Both Sexes | Males | Females | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Count | Percent | Rate | Count | Percent | Rate | Count | Percent | Rate | |
| Myelodysplastic Syndromes (MDS) | 28,138 | 100.0% | 4.5 | 16,274 | 100.0% | 6.2 | 11,864 | 100.0% | 3.3 |
| Refractory anemia (RA), NOS | 1,478 | 5.3% | 0.2 | 805 | 4.9% | 0.3 | 673 | 5.7% | 0.2 |
| RA with ringed sideroblasts | 1,640 | 5.8% | 0.3 | 936 | 5.8% | 0.4 | 704 | 5.9% | 0.2 |
| RA with excess blasts (RAEB) | 4,596 | 16.3% | 0.7 | 2,838 | 17.4% | 1.0 | 1,758 | 14.8% | 0.5 |
| RAEB in transformation | - | - | - | - | - | - | - | - | - |
| Refractory cytopenia w/multilineage dysplasia | 2,216 | 7.9% | 0.4 | 1,475 | 9.1% | 0.6 | 741 | 6.2% | 0.2 |
| Myelodysplastic syndrome with 5q deletion | 1,038 | 3.7% | 0.2 | 414 | 2.5% | 0.2 | 624 | 5.3% | 0.2 |
| Therapy-related myelodysplastic syndrome | - | - | - | - | - | - | - | - | - |
| Myelodysplastic syndrome, NOS | 17,170 | 61.0% | 2.7 | 9,806 | 60.3% | 3.8 | 7,364 | 62.1% | 2.0 |
Chronic Myeloproliferative Disorders (CMD)
| Site | Both Sexes | Males | Females | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Count | Percent | Rate | Count | Percent | Rate | Count | Percent | Rate | |
| Chronic Myeloproliferative Disorders (CMD) | 20,095 | 100.0% | 3.1 | 9,704 | 100.0% | 3.3 | 10,391 | 100.0% | 3.0 |
| Polycythemia vera | 8,347 | 41.5% | 1.3 | 4,672 | 48.1% | 1.6 | 3,675 | 35.4% | 1.0 |
| Chronic myeloproliferative disease, NOS | - | - | - | - | - | - | - | - | - |
| Myelosclerosis with myeloid metaplasia | 2,361 | 11.7% | 0.4 | 1,392 | 14.3% | 0.5 | 969 | 9.3% | 0.3 |
| Essential thrombocythemia | 9,145 | 45.5% | 1.4 | 3,493 | 36.0% | 1.2 | 5,652 | 54.4% | 1.7 |
| Chronic neutrophilic leukemia | 55 | 0.3% | 0.0 | 29 | 0.3% | 0.0 | 26 | 0.3% | 0.0 |
| Hypereosinophilic syndrome | 187 | 0.9% | 0.0 | 118 | 1.2% | 0.0 | 69 | 0.7% | 0.0 |
Chronic Myelomonocytic Leukemia (CMML)
| Site | Both Sexes | Males | Females | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Count | Percent | Rate | Count | Percent | Rate | Count | Percent | Rate | |
| Chronic Myelomonocytic Leukemia (CMML) | 2,961 | 100.0% | 0.5 | 1,854 | 100.0% | 0.7 | 1,107 | 100.0% | 0.3 |
Footnotes:
Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown due to fewer than 16 cases during the time period.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.